1. Multiple HLA-matched platelet transfusions for a single patient with broad anti-HLA antibodies: a case report
- Author
-
Sayuri Motomura, Tetsunori Tasaki, Fumihiro Azuma, Hisashi Tsutsumi, Yutaka Kato, Reina Matsui, Satoko Osanai, Takeshi Hagino, Hideo Ohtani, Hideki Akiyama, Chie Someya, Hiroko Hidai, and Nelson Hirokazu Tsuno
- Subjects
medicine.medical_specialty ,Refractory period ,business.industry ,Platelet Transfusion ,Hematology ,General Medicine ,Human leukocyte antigen ,Gastroenterology ,Platelet transfusion refractoriness ,Single patient ,HLA Antigens ,Internal medicine ,Statistical significance ,medicine ,Humans ,Female ,Hla antibodies ,Platelet ,Platelet concentrate ,business ,Aged - Abstract
The efficacy of 30 platelet concentrate (PC) products transfused to a patient with myelodysplastic syndrome (MDS) was evaluated by calculating the 1-hour post-transfusion corrected count increment (1h-CCI). Of the 30 transfusions, all HLA-A/B-matched, the cross-match (CM) test was negative in 23 (CM(-)-PC) and weakly positive (CM(+)-PC) in 2, and the CM test was not conducted in 5 (non-CM-PC). The effective rate was higher with CM(-)-PC compared to non-CM-PC (82.6% vs 60%), but statistical significance was not achieved, which suggested that the CM test of PC may still be a not satisfactorily effective predictor of PC refractoriness. Studies are ongoing in Japan to confirm on the importance of CM test of PC.
- Published
- 2019
- Full Text
- View/download PDF